SubHero Banner

Nexlizet (bempedoic acid/ezetimibe) – New drug approval

February 26, 2020 - Esperion announced the FDA approval of Nexlizet (bempedoic acid/ezetimibe), as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Download PDF